Tyra Biosciences, Inc. (TYRA) is a precision oncology company centered around discovery and development of breakthrough cancer therapeutics. It focuses on creating and innovating targeted therapies that tackle undrugged oncogenic drivers in a wide range of tumor types.
The company looks to become a leader in advancing the understanding of biological complexity in cancer, leveraging advanced science and technology to develop personalized treatments. They utilize their novel, proprietary platform ENCOMPASS to create small molecule therapeutics that directly address the root cause of cancer, and not just the symptoms.
Tyra Biosciences' primary focus is on oncogenic mutations which previous scientific research struggled to target. ENCOMPASS, their drug discovery platform, utilizes both proprietary and public data to identify the best cancer drug targets by considering mutational bias. It leverages the knowledge that cancer mutations are not random but biased due to the effect of natural selection on tumor evolution.
Tyra Biosciences was founded with a mission to address the unmet need in cancer treatment through precision medicine. Teaming up with academic institutions, quality investors, and a top-tier team, the company combines broad scientific expertise with an unrelenting drive towards cancer treatment innovation, setting them apart.
The company is led by a management team with significant experience in oncology and drug discovery and development. Their dedicated team of scientists, clinicians, and drug developers has a shared vision of developing novel therapeutics that have the potential to dramatically improve cancer patient retorts.
One of Tyra Biosciences’ recent developments includes a lead program, TYRA-223, which targets mutant NRAS. This critical oncogenic driver is frequent in melanoma, acute myeloid leukemia, and other tumors, yet there's been limited progress to therapeutically target it significantly.
Tyra Biosciences, Inc. launched its initial public offering (IPO) on the NASDAQ Exchange in July 2021. Furthering their mission, this move serves to support key clinical trials, advance their pipeline, and make headways in ending the fight against cancer.
Overall, Tyra Biosciences, Inc. is on a clear path to shift the landscape of targeted therapies for oncogenic mutations. With their deep commitment to science and innovation, they are poised to bring significant advancements in the battle against cancer. Their work aspires beyond treating cancer; it wants to empower patients in their fight and deliver a chance at a disease-free life. Through their groundbreaking research and novel approaches, the future of Tyra Biosciences seems hopeful and full of potential.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Tyra Biosciences (NASDAQ:TYRA) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $47.20. The company's stock opened at $19.34, significantly below this target, and institutional investors hold a substantial 84.14% of its shares. Recent analyst actions have shown mixed revisions to price targets, while Tyra Biosciences continues to develop TYRA-300 for FGFR3-driven cancers.
Tyra Biosciences stock has seen a 31.8% gain over the past three years, but its current market price appears expensive when compared to its book value. Trading at 3.6x book value, which is double the biotech industry average, suggests investors are paying a premium for its net assets. The company is still loss-making, making book value a critical metric for investors to consider.
This article analyzes Tyra Biosciences Inc. (NASDAQ: TYRA), highlighting weak near and mid-term sentiment but a positive long-term outlook. It provides AI-generated trading strategies for different risk profiles, including long, breakout, and short positions, along with multi-timeframe signal analysis for support and resistance levels.
Tyra Biosciences (TYRA) has experienced a 27% stock price drop in the last four weeks, but indicators suggest a potential turnaround. The stock is currently in oversold territory according to its Relative Strength Index (RSI) of 29.84, and analysts have raised earnings estimates for the current year. Furthermore, TYRA holds a Zacks Rank #2 (Buy), indicating strong potential for near-term price appreciation.